

Effectiveness of electronic cigarettes compared with combination nicotine replacement therapy for smoking cessation in patients with chronic obstructive pulmonary disease and effect on lung health (ECAL Trial)

Submission date 03/05/2023	Recruitment status No longer recruiting	☒ Prospectively registered ☒ Protocol
Registration date 04/10/2023	Overall study status Ongoing	☐ Statistical analysis plan ☐ Results
Last Edited 07/01/2026	Condition category Respiratory	☐ Individual participant data ☒ Record updated in last year

Plain English summary of protocol

Background and study aims

Chronic obstructive pulmonary disease (COPD) is a common lung condition which mainly affects adults aged 35 years and older, and it is most often caused by smoking. COPD symptoms tend to get gradually worse over time and can limit normal activities. Smoking speeds up the progression of COPD but it can be extremely hard to quit, and people with COPD tend to have a greater dependence on nicotine. There are several different treatments available that increase people's chances of successfully quitting smoking; however, many people still relapse back to smoking. Electronic cigarettes (e-cigs) are not currently available on NHS prescription but could help COPD patients to quit smoking. Our goal with this research is to find out how effective e-cigs are compared with combination NRT in helping COPD patients quit smoking cigarettes, and which treatment is more cost-effective for the NHS. The data collected during this trial will also be used to inform a lung health sub-study and wellbeing sub-study. The lung health sub-study will look at the effects of switching to vaping on clinical, physiological and cellular measures of lung health between vapers, continued smokers and quitters. The well-being sub-study will look at the effect of switching to vaping on anxiety, depression and social quality of life compared to those who smoke and quitters.

Who can participate?

People aged 35 years and older who have been identified from selected GP practices and NHS hospitals in England, Wales and Scotland, diagnosed with COPD and are current smokers who want to try to stop smoking

What does the study involve?

This multi-centre trial will invite potentially eligible patients identified from selected GP practices and NHS hospitals in England, Wales and Scotland. Trial participants will be followed up for 1 year. All participants will be asked to have two face-to-face clinic visits to undertake

lung function tests and blood tests. Participants will also receive behaviour support calls from a smoking cessation advisor at set time points through the follow-up period.

What are the possible benefits and risks of participating?

All participants will receive support to stop smoking. There is a potential that participants may be successful in quitting smoking and see an improvement in their health. The products used in this trial are widely used for smoking cessation in standard practice and can be bought over the counter. Participants have no higher risk of side effects than if they were to receive either treatment as part of standard care. The use of nicotine-containing products can result in mild side effects and the main participant information sheet (PIS) advises of these and explains what to do/ who to contact if they experience issues. The participants' GPs will be notified about their participation in the trial, and they will be advised to monitor their patients whilst they try to quit smoking.

Where is the study run from?

University of Birmingham (UK)

When is the study starting and how long is it expected to run for?

September 2022 to January 2027

Who is funding the study?

National Institute for Health and Care Research (NIHR) (UK)

Who is the main contact?

Birmingham Clinical Trials Unit, ECAL@trials.bham.ac.uk (UK)

Contact information

Type(s)

Principal investigator

Contact name

Prof David Thickett

ORCID ID

<https://orcid.org/0000-0002-5456-6080>

Contact details

Centre for Translational Inflammation Research

Queen Elizabeth Hospital

Institute of Inflammation and Ageing

University of Birmingham

Edgbaston

Birmingham

United Kingdom

B15 2SQ

+44 (0)121 371 3231

d.thickett@bham.ac.uk

Type(s)

Scientific

Contact name

Dr Amanda Farley

ORCID ID

<https://orcid.org/0000-0002-4370-0264>

Contact details

Institute of Applied Health Research
University of Birmingham
Edgbaston
Birmingham
United Kingdom
B15 2TT
None available
a.c.farley@bham.ac.uk

Type(s)

Public

Contact name

Dr Birmingham Clinical Trials Unit

Contact details

Institute of Applied Health Research
College of Medical and Dental Sciences
Public Health Building
University of Birmingham
Birmingham
United Kingdom
B15 2TT
+44 (0)121 414 8137
ECAL@trials.bham.ac.uk

Additional identifiers**Integrated Research Application System (IRAS)**

1006828

Central Portfolio Management System (CPMS)

56604

Protocol serial number

RG_20-120

Study information

Scientific Title

Effectiveness of electronic cigarettes compared with combination nicotine replacement therapy for smoking cessation in patients with chronic obstructive pulmonary disease and effect on lung health (ECAL Trial)

Acronym

ECAL

Study objectives

To investigate the effectiveness and cost-effectiveness of Electronic Cigarettes for quitting smoking compared with combination Nicotine Replacement Therapy as an aid to smoking cessation.

To explore change in lung and mental health in people who switch to vaping compared with people who quit smoking without vaping, and people who continue to smoke.

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 03/10/2023, North East - Newcastle & North Tyneside 2 Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 (0)207 104 8086; newcastlenorthtyneside2.rec@hra.nhs.uk), ref: 23/NE/0102

Primary study design

Interventional

Study design

Multicentre two-arm randomized controlled trial with embedded cost-effectiveness and cohort analyses

Study type(s)

Efficacy, Prevention

Health condition(s) or problem(s) studied

Chronic obstructive pulmonary disease (COPD)

Interventions

Intervention arm: Electronic Cigarettes (EC) - At the baseline visit, participants will be given an EC starter pack and an initial supply of e-liquid (up to 20 mg nicotine/ml). Participants will be provided with instructions on how to continue sourcing further supplies themselves from reputable vendors in their preferred nicotine strength and flavours.

Comparator arm: Combination Nicotine Replacement Therapy (NRT) - Participants will receive up to a 12-week supply of a nicotine patch plus a fast-acting nicotine product to be used in combination. Participants who do not wish to use patches (e.g. due to previous experience with skin irritation) will be offered two types of fast-acting products.

Telephone behavioural support: All participants (intervention and comparator arm) will be advised at the baseline visit that they will receive six weekly behavioural support telephone calls from stop-smoking advisors which will commence within a few days of the baseline visit. During

these calls, the advisor will deliver behavioural support according to the National Centre for Smoking Cessation Training Standard Programme including setting a TQD and providing further support around medication use.

Intervention Type

Drug

Phase

Phase III

Drug/device/biological/vaccine name(s)

Electronic cigarettes with e-liquid (up to 20 mg nicotine/ml), nicotine patch, fast-acting nicotine product

Primary outcome(s)

Abstinence from smoking since target quit date (TQD) biochemically validated (exhaled CO<8ppm), defined in accordance with the Russell Standard. This will be measured with a questionnaire and exhaled carbon monoxide measurement at 52 weeks post-TQD

Key secondary outcome(s)

1. Abstinence from smoking for at least 26 weeks biochemically validated (exhaled CO <8 ppm) measured using a questionnaire at 52 weeks
2. 7-day point prevalence abstinence from smoking biochemically validated (exhaled CO <8 ppm) measured using a questionnaire at 52 weeks
3. Self-reported abstinence from smoking for at least 26 weeks measured using a questionnaire at 52 weeks
4. Self-reported 7-day point prevalence abstinence from smoking measured using a questionnaire at 4, 26 and 52 weeks
5. Reduction in cigarettes smoked (self-report of any and > 50% reduction) from baseline to 52 weeks measured using a questionnaire, confirmed by reductions in expired CO readings at 52 weeks
6. Reduction in cigarettes smoked (self-report of any and > 50% reduction) from baseline to 26 /52 weeks measured using a questionnaire
7. Continued use of the allocated product measured using a questionnaire at 4, 26 and 52 weeks
8. Withdrawal symptoms and urges to smoke (change from baseline to 1/2/3/4 week) measured using the mood and physical symptom scale (MPSS)
9. COPD Symptoms (change from baseline to 4/26/52 week) measured using COPD Assessment Test (CAT) and the Clinical COPD Questionnaire (CCQ)
10. Number of COPD exacerbations over the past 52 weeks (change from baseline to 52 weeks) measured using a questionnaire
11. Number of self-reported upper respiratory tract over the past 52 weeks (change from baseline to 52 weeks) measured using a questionnaire
12. Post bronchodilator spirometry (FEV1, FVC and MMEF change from baseline to 52 weeks). Forced Expiratory Volume in 1 Second (FEV1): The maximal volume of air that can be expired in the first second of a forced expiration from a position of full inspiration (measured in Litres (L) and also expressed as the % predicted for age, sex, height and race). Forced Vital Capacity (FVC): The maximal volume of air that can be expired during a forced and complete expiration from a position of full inspiration (measured in L and % predicted). Mean Mid-Expiratory Flow (MMEF): The average flow between 25% and 75% of the FVC manoeuvre (measured in L/sec and % predicted).

Health economic outcomes:

1. Health-related quality of life (EQ-5D-5L) measured using a questionnaire change from baseline to 4/26/52 weeks
2. Use of healthcare resources and costs measured using a questionnaire at 26 and 52 weeks
3. Cost-effectiveness based on cost per quitter and cost per Quality-Adjusted Life-Year (QALY) at 52 weeks, and modelled cost per QALY over a patient's lifetime

Completion date

05/01/2027

Eligibility

Key inclusion criteria

Current inclusion criteria as of 07/01/2026:

1. COPD diagnosis confirmed by post-bronchodilator spirometry (FEV1/FVC <0.7), any GOLD stage
2. Current daily smoker
3. Willing to try to stop smoking using only allocated trial products
4. Aged 35 years or over

Previous inclusion criteria:

1. COPD diagnosis previously confirmed by post-bronchodilator spirometry (FEV1/FVC <0.7), any GOLD stage
2. Current smoker (≥ 5 cigarettes per day)
3. Motivated to stop smoking
4. Aged 35 years or over

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

35 Years

Upper age limit

100 Years

Sex

All

Total final enrolment

141

Key exclusion criteria

Current exclusion criteria as of 07/01/2026:

1. Unable to perform spirometry to a satisfactory standard (e.g. due to dementia, lack of teeth, lack of coordination or not having a good oral seal)
2. Deemed as unsuitable to participate in the trial (e.g. terminal illness, unable to give informed consent)
3. Unable to participate in behaviour support calls
4. Severe angina or unstable cardiovascular disease
5. History of end stage kidney disease
6. History of cirrhosis of the liver
7. Currently taking part in another trial of smoking cessation or COPD treatment/management
8. Contraindications to spirometry within the last 12 weeks – tuberculosis infection, cardiac infarction, retinal detachment, Pneumothorax or surgery on the chest, abdomen, brain, ears or eyes (invite back and re-assess after 12 weeks)

Previous exclusion criteria:

1. Unable to perform spirometry to a satisfactory standard (e.g. due to dementia, lack of teeth, lack of coordination or not having a good oral seal)
2. Deemed as unsuitable to participate in the trial (e.g. terminal illness, unable to give informed consent)
3. Unable to participate in behaviour support calls
4. Severe angina or unstable cardiovascular disease
5. History of end stage kidney disease
6. History of cirrhosis of the liver
7. Currently taking NRT, bupropion, varenicline or ECs to stop or reduce smoking
8. Currently taking part in another trial of smoking cessation or COPD treatment/management
9. COPD exacerbation or inpatient hospital stay within the last 8 weeks (invite back and re-assess after 8 weeks)
10. Contraindications to spirometry within the last 12 weeks – tuberculosis infection, cardiac infarction, retinal detachment or surgery on the chest, abdomen, brain, ears or eyes (invite back and re-assess after 12 weeks)

Date of first enrolment

26/06/2024

Date of final enrolment

21/11/2025

Locations

Countries of recruitment

United Kingdom

England

Scotland

Wales

Study participating centre

University Hospitals Birmingham NHS Foundation Trust

Queen Elizabeth Hospital
Mindelsohn Way
Edgbaston
Birmingham
England
B15 2GW

Study participating centre

Leeds Teaching Hospitals NHS Trust

St. James's University Hospital
Beckett Street
Leeds
England
LS9 7TF

Study participating centre

Gateshead Health NHS Foundation Trust

Queen Elizabeth Hospital
Sheriff Hill
Gateshead
England
NE9 6SX

Study participating centre

The Shrewsbury and Telford Hospital NHS Trust

Mytton Oak Road
Shrewsbury
England
SY3 8XQ

Study participating centre

Mid and South Essex NHS Foundation Trust

Broomfield Hospital, Court Rd, Broomfield
Chelmsford
England
CM1 7ET

Study participating centre

South Tees Hospitals NHS Foundation Trust

James Cook University Hospital

Marton Road
Middlesbrough
England
TS4 3BW

Study participating centre
University Hospitals Sussex NHS Foundation Trust
Royal Sussex County Hospital, Eastern Rd
Brighton
England
BN2 5BE

Study participating centre
Sherwood Forest Hospitals NHS Foundation Trust
Kings Mill Hospital
Mansfield Road
Sutton-in-ashfield
England
NG17 4JL

Study participating centre
The Dudley Group NHS Foundation Trust
Russells Hall Hospital
Pensnett Road
Dudley
England
DY1 2HQ

Study participating centre
Healthcare Central London Ltd & Central London Healthcare CIC
South Westminster Centre, St Georges House, 82 Vincent Square
London
England
SW1P 2PF

Study participating centre
Betsi Cadwaladr University Health Board
Glan Clwyd Hospital
Rhyl
Wales
LL18 5UJ

Study participating centre

The Confederation Hillingdon Cic
Pembroke Centre, 90 Pembroke Rd
Ruislip
England
HA4 8NX

Study participating centre

Tameside and Glossop Integrated Care NHS Foundation Trust
Tameside General Hospital
Fountain Street
Ashton-under-lyne
England
OL6 9RW

Study participating centre

Manchester University NHS Foundation Trust
Wythenshawe Hospital, Southmoor Rd, Wythenshawe
Manchester
England
M23 9LT

Study participating centre

Manchester University NHS Foundation Trust
North Manchester General Hospital, Delaunays Rd, Crumpsall
Manchester
England
M8 5RB

Study participating centre

Vauxhall Primary Health Care
Vauxhall Health Centre, 111-117 Limekiln Lane
Liverpool
England
L5 8XR

Sponsor information

Organisation
University of Birmingham

ROR
<https://ror.org/03angcq70>

Funder(s)

Funder type
Government

Funder Name
National Institute for Health and Care Research

Alternative Name(s)
National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

Funding Body Type
Government organisation

Funding Body Subtype
National government

Location
United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan
The data-sharing plans for the current study are unknown and will be made available at a later date

IPD sharing plan summary
Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol (other)			30/12/2025	No	No
Study website		11/11/2025	11/11/2025	No	Yes